Jul202017 Anavex Life Sciences Appoints Distinguished Researcher in Neurology and Epilepsy to Scientific Advisory Board July 20, 2017
Anavex Life Sciences Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders Including Angelman Syndrome − Data Presented at Antiepileptic Drug Trials XIV 2017 Conference May 22, 2017
May222017 Anavex Life Sciences Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders Including Angelman Syndrome − Data Presented at Antiepileptic Drug Trials XIV 2017 Conference − May 22, 2017
May172017 Anavex President & CEO Christopher U. Missling, PhD, to present preclinical data on ANAVEX 2-73™ at the Epilepsy Foundation’s Antiepileptic Drug Trials XIV Conference on May 19. May 17, 2017
May12017 Anavex Life Sciences Appoints Former FDA Officer as Senior Vice President of Regulatory Affairs May 1, 2017
Anavex President & CEO Christopher U. Missling, PhD, to participate in a roundtable discussion at the World Orphan Drug Congress USA, on April 21. April 21, 2017
Apr32017 Anavex Life Sciences Reports New Mechanism of Action Data Related to ANAVEX Compounds Targeting Sigma-1 Receptor April 3, 2017
